featured
Efficacy and Safety of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction by Baseline Glycaemic Status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
Lancet Diabetes Endocrinol 2022 Nov 10;[EPub Ahead of Print], SE Inzucchi, BL Claggett, M Vaduganathan, AS Desai, PS Jhund, RA de Boer, AF Hernandez, MN Kosiborod, CSP Lam, F Martinez, SJ Shah, S Verma, Y Han, JF Kerr Saraiva, O Bengtsson, M Petersson, AM Langkilde, JJV McMurray, SD SolomonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.